National Institute of Allergy and Infectious Diseases (NIAID): Hemorrhagic Fever, Ebola trials

The registry lists 18 Hemorrhagic Fever, Ebola studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 11Phase 2 5Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy AdultsCompletedNCT04041570Phase 1Results posted
• Investigational Therapeutics for the Treatment of People With Ebola Virus DiseaseCompletedNCT03719586Phase 2/3Results posted
• A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)CompletedNCT03583606Phase 1Results posted
• Partnership for Research on Ebola VACcinationsCompletedNCT02876328Phase 2Results posted
• GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in SemenCompletedNCT02818582Phase 2Results posted
• Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola InfectionCompletedNCT02363322Phase 1/2Results posted
• Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)CompletedNCT02344407Phase 2Results posted
• Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL IIICompletedNCT05494801
• Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope GlycoproteinTerminatedNCT03462004Phase 1
• PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine ResponseCompletedNCT03098862
• A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy VolunteersCompletedNCT02891980Phase 1
• Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsCompletedNCT02564575Phase 1
• Ebola Virus Disease Survivors: Clinical and Immunologic Follow-upCompletedNCT02431923
• Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in UgandaCompletedNCT02354404Phase 1
• Evaluating an Ebola and a Marburg Vaccine in UgandaCompletedNCT00997607Phase 1
• Ebola and Marburg Virus VaccinesCompletedNCT00605514Phase 1
• Experimental Vaccine for Prevention of Ebola Virus InfectionCompletedNCT00374309Phase 1
• Experimental Ebola Vaccine TrialCompletedNCT00072605Phase 1